Akebia Therapeutics, Inc. (AKBA) Stock Analysis

Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results

Mon, May 11, 2026 at 12:27 PM UTC 3 min read

Analysts have revised their estimates for Akebia Therapeutics, Inc. (NASDAQ: AKBA) following the company's first-quarter results, which revealed key financial metrics and operational updates. This adjustment reflects a reassessment of the company's growth potential and market position, providing investors with updated insights into its performance trajectory. The changes could influence investment decisions as stakeholders evaluate the company's future prospects in the biopharmaceutical sector.

Read full article →

Akebia (AKBA) Q1 2026 Earnings Transcript

Fri, May 8, 2026 at 3:12 PM UTC 3 min read

Akebia (AKBA) reported its Q1 2026 earnings, highlighting a significant increase in revenue driven by strong sales of its lead product, vadadustat. The company also announced advancements in its clinical pipeline, which could enhance its market position. For investors, these developments suggest potential for growth and improved financial performance, reinforcing confidence in Akebia's long-term strategy.

Read full article →